Evidence map›Paper›PMID 33015133›Full record

ReviewFrontiers in molecular biosciences2020

Role of Transmembrane 4 L Six Family 1 in the Development and Progression of Cancer.

Fangmei Fu, Xudong Yang, Minying Zheng, Qi Zhao, Kexin Zhang, Zugui Li, Hao Zhang, Shiwu Zhang

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. YBX1 Enhances the Stability of TM4SF1 in an mCombinatorial chemistry & high throughput screening · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Integrative Computational Framework,bioRxiv : the preprint server for biology · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?Diagnostics (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Fangmei FuGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Xudong YangTianjin Rehabilitation Center, Tianjin, China.
Minying ZhengDepartment of Pathology, Tianjin Union Medical Center, Tianjin, China.
Qi ZhaoGraduate School, Tianjin Medical University, Tianjin, China.
Kexin ZhangNankai University School of Medicine, Nankai University, Tianjin, China.
Zugui LiGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Hao ZhangGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Shiwu ZhangDepartment of Pathology, Tianjin Union Medical Center, Tianjin, China.
Tianjin University of Traditional Chinese Medicine · CNTianjin People's Hospital · CNNankai University · CNTianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transmembrane 4 L six family 1 (TM4SF1) is a protein with four transmembrane domains that belongs to the transmembrane 4 L six family members (TM4SFs). Structurally, TM4SF1 consists of four transmembrane domains (TM1-4), N- and C-terminal intracellular domains, two extracellular domains, a smaller domain between TM1 and TM2, and a larger domain between TM3 and TM4. Within the cell, TM4SF1 is located at the cell surface where it transmits extracellular signals into the cytoplasm. TM4SF1 interacts with tetraspanins, integrin, receptor tyrosine kinases, and other proteins to form tetraspanin-enriched microdomains. This interaction affects the pro-migratory activity of the cells, and thus it plays important roles in the development and progression of cancer. TM4SF1 has been shown to be overexpressed in many malignant tumors, including gliomas; malignant melanomas; and liver, prostate, breast, pancreatic, bladder, colon, lung, gastric, ovarian, and thyroid cancers. TM4SF1 promotes the migration and invasion of cancer cells by inducing epithelial-mesenchymal transition, self-renewal ability, tumor angiogenesis, invadopodia formation, and regulating the related signaling pathway. TM4SF1 is an independent prognostic indicator and biomarker in several cancers. It also promotes drug resistance, which is a major cause of therapeutic failure. These characteristics make TM4SF1 an attractive target for antibody-based immunotherapy. Here, we review the many functions of TM4SF1 in malignant tumors, with the aim to understand the interaction between its expression and the biological behaviors of cancer and to supply a basis for exploring new therapeutic targets.

Indexed as

cancermigrationprogressionsignaling pathwayTM4SF1

Identifiers

PMID33015133
PMCPMC7461813
OpenAlexW3059664894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.